Heligenics Unveils A First-Of-Its-Kind Precision Prescription Test For Breast Cancer Therapeutics
2023-06-14
Using our proprietary GigaAssay technology we can rapidly determine which of the 10,000s of mutants would make a breast cancer patient susceptible to a drug they would want to take
Heligenics revolutionized selection of the right drug with its first-of-its-kind genetic test for breast cancer that chooses among 3 FDA-approved drugs. (Credit: National Cancer InstituteCancer Institute on Unsplash)
Heligenics, a cutting-edge biotech company, announces a first-of-its-kind precision genetic test to select among drugs to treat breast cancer.
There are multiple drugs available to treat breast cancer. Most patients become drug resistant, meaning that the cancer cells aren’t responding to the drug that is usually able to kill or weaken them.
Although many patients eventually die from acquiring resistance to a drug, there is no systematic approach to identifying the variants that cause target-derived drug resistance. There are over 10,000 potential mutations in a cancer gene and we have no idea which ones produce resistance. It would be great if we could match the therapy to the genetics of the tumor, but as of today there is little rationale for choosing among drugs. Heligenics revolutionized selection of the right drug with its first-of-its-kind genetic test for breast cancer that chooses among 3 FDA-approved drugs.
Using our proprietary GigaAssay technology we can rapidly determine which of the 10,000s of mutants would make a breast cancer patient susceptible to a drug they would want to take. Heligenics also identifies which of these variants produced resistance to the drug. Heligenics has started with 3 breast cancer drugs called Tykerb, Tukysa, and Nerlynx. This will transform analysis of biopsies to create a data-driven approach to treatment.
Dr. Jerome Rotter, a board member of Heligenics and Director of Translational Genomics and Population Sciences at the Lundquist Institute / Harbor-UCLA said, “This test is a great example of the future of personalized drug therapy.”
Source: Company Press Release
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。